Jurkovic Mlakar, Simona; Uppugunduri, Satyanarayana Chakradhara Rao; Nava, Tiago; Mlakar, Vid; Golay, Hadrien; Robin, Shannon; Waespe, Nicolas; Rezgui, Mohamed Aziz; Chalandon, Yves; Boelens, Jaap Jan; Bredius, Robert G M; Dalle, Jean-Hugues; Peters, Christina; Corbacioglu, Selim; Bittencourt, Henrique; Krajinovic, Maja; Ansari, Marc (2022). GSTM1 and GSTT1 double null genotypes determining cell fate and proliferation as potential risk factors of relapse in children with hematological malignancies after hematopoietic stem cell transplantation. Journal of cancer research and clinical oncology, 148(1), pp. 71-86. Springer 10.1007/s00432-021-03769-2
|
Text
JurkovicMlakar_JCancerResClinOncol_2022.pdf - Published Version Available under License Creative Commons: Attribution (CC-BY). Download (2MB) | Preview |
PURPOSE
This study aimed to retrospectively evaluate the genetic association of null variants of glutathione S-transferases GSTM1 and GSTT1 with relapse incidence in children with hematological malignancies (HMs) undergoing busulfan (BU)- containing allogeneic hematopoietic stem cell transplantation (HSCT) and to assess the impact of these variants on BU-induced cytotoxicity on the immortalized lymphoblastoid cell lines (LCLs) and tumor THP1 GST gene-edited cell models.
METHODS
GSTM1- and GSTT1-null alleles were genotyped using germline DNA from whole blood prior to a conditioning BU-based regimen. Association of GSTM1- and GSTT1-null variants with relapse incidence was analyzed using multivariable competing risk analysis. BU-induced cell death studies were conducted in GSTs- null and non-null LCLs and CRISPR-Cas9 gene-edited THP1 leukemia cell lines.
RESULTS
Carrying GSTM1/GSTT1 double null genotype was found to be an independent risk factor for post-HSCT relapse in 86 children (adjusted HR: 6.52 [95% Cl, 2.76-15.42; p = 1.9 × 10-5]). BU-induced cell death preferentially in THP1GSTM1(non-null) and LCLsGSTM1(non-null) as shown by decreased viability, increased necrosis and levels of the oxidized form of glutathione compared to null cells, while GSTT1 non-null cells showed increased baseline proliferation.
CONCLUSION
The clinical association suggests that GSTM1/GSTT1 double null genotype could serve as genetic stratification biomarker for the high risk of post-HSCT relapse. Functional studies have indicated that GSTM1 status modulates BU-induced cell death. On the other hand, GSTT1 is proposed to be involved in baseline cell proliferation.
Item Type: |
Journal Article (Original Article) |
---|---|
Division/Institute: |
04 Faculty of Medicine > Pre-clinic Human Medicine > Institute of Social and Preventive Medicine (ISPM) |
UniBE Contributor: |
Waespe Laredo, Nicolas Thomas |
Subjects: |
600 Technology > 610 Medicine & health 300 Social sciences, sociology & anthropology > 360 Social problems & social services |
ISSN: |
1432-1335 |
Publisher: |
Springer |
Funders: |
[4] Swiss National Science Foundation |
Language: |
English |
Submitter: |
Andrea Flükiger-Flückiger |
Date Deposited: |
17 Sep 2021 09:58 |
Last Modified: |
29 Dec 2022 12:18 |
Publisher DOI: |
10.1007/s00432-021-03769-2 |
PubMed ID: |
34499222 |
Uncontrolled Keywords: |
Acute leukemia Busulfan resistance Hematological malignancies Hematopoietic stem cell transplantation Null genotypes of glutathione S-transferases Post-transplant relapse |
BORIS DOI: |
10.48350/159349 |
URI: |
https://boris.unibe.ch/id/eprint/159349 |